Citations

Clear

4847 citation(s) found for "Tu, Eric".

Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients
Hellkamp, Anne S., Curtis, Lesley H. , Hammill, Stephen C., Masoudi, Frederick A. , Bhatt, Deepak L. , Al‐Khalidi, Hussein R. , Heidenreich, Paul A. , Anstrom, Kevin J. , Fonarow, Gregg C. , Pokorney, Sean D, Yancy, Clyde W. , Al-Khalidi, Hussein R, Al-Khatib, Sana M, Pokorney, Sean D. , Peterson, Eric D. , Al‐Khatib, Sana M. , Bhatt, Deepak L

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | December 13, 2014 | Volume: 8 | Issue: 1 | Pages: 145-151

10.1161/circep.114.001878 | PMID 25504649 Get It

Background— Racial and ethnic minorities are under-represented in clinical trials of primary prevention implantable cardioverter-defibrillators (ICDs). This analysis investigates the association between primary prevention ICDs and mortality among Medicare, racial/ethnic minority patients. Methods and Results— Data from Get With The Guidelines-Heart Failure Registry and National Cardiovascular Data Registry’s ICD Registry were used to perform an adjusted comparative effectiveness analysis of primary prevention ICDs in Medicare, racial/ethnic minority patients (nonwhite race or Hispanic ethnicity). Mortality data were obtained from the Medicare denominator file. The relationship of ICD with survival was compared between minority and white non-Hispanic patients. Our analysis included 852 minority patients, 426 ICD and 426 matched non-ICD patients, and 2070 white non-Hispanic patients (1035 ICD and 1035 matched non-ICD patients). Median follow-up was 3.1 years. Median age was 73 years, and median ejection fraction was 23%. Adjusted 3-year mortality rates for minority ICD and non-ICD patients were 44.9% (95% confidence interval [CI], 44.2%–45.7%) and 54.3% (95% CI, 53.4%–55.1%), respectively (adjusted hazard ratio, 0.79; 95% CI, 0.63–0.98; P =0.034). White non-Hispanic patients receiving an ICD had lower adjusted 3-year mortality rates of 47.8% (95% CI, 47.3%–48.3%) compared with 57.3% (95% CI, 56.8%–57.9%) for those with no ICD (adjusted hazard ratio, 0.75; 95% CI, 0.67%–0.83%; P <0.0001). There was no significant interaction between race/ethnicity and lower mortality risk with ICD ( P =0.70). Conclusions— Primary prevention ICDs are associated with lower mortality in nonwhite and Hispanic patients, similar to that seen in white, non-Hispanic patients. These data support a similar approach to ICD patient selection, regardless of race or ethnicity.
Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation
Kim, Sunghee , Thomas, Laine , Fonarow, Gregg C. , Kowey, Peter R. , Mahaffey, Kenneth W. , Sherwood, Matthew W. , Chang, Paul, Piccini, Jonathan P. , Ansell, Jack , Steinberg, Benjamin A. , Peterson, Eric D. , Gersh, Bernard J.

Mayo Clinic

Circulation | December 12, 2014 | Volume: 131 | Issue: 5 | Pages: 488-494

10.1161/circulationaha.114.011777 | PMID 25499873 Get It

Background— Temporary interruption of oral anticoagulation for procedures is often required, and some propose using bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions in clinical practice are unknown. Methods and Results— The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry is a prospective, observational registry study of US outpatients with atrial fibrillation. We recorded incident temporary interruptions of oral anticoagulation for a procedure, including the use and type of bridging therapy. Outcomes included multivariable-adjusted rates of myocardial infarction, stroke or systemic embolism, major bleeding, cause-specific hospitalization, and death within 30 days. Of 7372 patients treated with oral anticoagulation, 2803 overall interruption events occurred in 2200 patients (30%) at a median follow-up of 2 years. Bridging anticoagulants were used in 24% (n=665), predominantly low-molecular-weight heparin (73%, n=487) and unfractionated heparin (15%, n=97). Bridged patients were more likely to have had prior cerebrovascular events (22% versus 15%; P =0.0003) and mechanical valve replacements (9.6% versus 2.4%; P <0.0001); however, there was no difference in CHA 2 DS 2 -VASc scores (scores ≥2 in 94% versus 95%; P =0.5). Bleeding events were more common in bridged than nonbridged patients (5.0% versus 1.3%; adjusted odds ratio, 3.84; P <0.0001). The incidence of myocardial infarction, stroke or systemic embolism, major bleeding, hospitalization, or death within 30 days was also significantly higher in patients receiving bridging (13% versus 6.3%; adjusted odds ratio, 1.94; P =0.0001). Conclusions— Bridging anticoagulation is used in one quarter of anticoagulation interruptions and is associated with higher risk for bleeding and adverse events. These data do not support the use of routine bridging, and additional data are needed to identify best practices concerning anticoagulation interruptions. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01165710.
Steatorrhea Complicating Diabetes Mellitus with Neuropathy: Report of Cases without Apparent External Pancreatic Insufficiency
Berge, Kenneth G., Wollaeger, Eric E., Scholz, D, Rooke, E. Douglas , Sprague, Randall G.

Mayo Clinic

Diabetes | December 11, 2014 | Volume: 5 | Issue: 1 | Pages: 25-31

10.2337/diab.5.1.25 | PMID 13294004 Get It

Disturbances of gastrointestinal function have frequently been observed in association with diabetes mellitus. The disorders which have been reported include gastric atony and dilatation, postprandial abdominal cramping, severe constipation, and intractable diarrhea characterized by watery stools, nocturnal exacerbations and fecal incontinence. These disturbances have been attributed by many investigators to alterations in gastrointestinal motility secondary to visceral diabetic neuropathy. The purpose of the present report is to call attention to a group of patients with diabetes mellitus and neuropathy who exhibited diarrhea and steatorrhea which apparently could not be attributed to external pancreatic insufficiency.
Pearls & Oy-sters: HyperCKemia with limb-girdle weakness
Ghosh, Partha S. , Lahoria, Rajat , Milone, Margherita , Sorenson, Eric J.

Mayo Clinic

Neurology | December 8, 2014 | Volume: 83 | Issue: 24 | Pages: No page available

10.1212/wnl.0000000000001071 | PMID 25488998 Get It

Establishment of the Cancer Prevention Study II Nutrition Cohort Colorectal Tissue Repository
Deka, Anusila , Cicek, Mine , Farris, Alton B. , Gaudet, Mia M. , Jacobs, Eric J. , Newton, Christina C. , Patel, Alpa V. , Thibodeau, Stephen N. , Tillmans, Lori S. , Gapstur, Susan M. , Tillmans, Lori, Campbell, Peter T. , Briggs, Peter , Teras, Lauren R. , Farris, Alton B

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 3, 2014 | Volume: 23 | Issue: 12 | Pages: 2694-2702

10.1158/1055-9965.epi-14-0541 | PMID 25472679 Get It

Abstract Background: To better understand colorectal cancer etiology and prognosis, archived surgical tissues were collected from Cancer Prevention Study II (CPS-II) Nutrition Cohort participants who were diagnosed with colorectal cancer. Herein, the methodology for this collection is described to help inform other efforts to collect tissues. Methods: The main components to accruing tissue were: (i) obtaining consent from participants or next-of-kin; (ii) contacting hospitals to request materials; and (iii) pathology review and laboratory processing. Results: In CPS-II, we identified 3,643 participants diagnosed with colorectal cancer between 1992/1993 and 2009. Of these, tissue could not be sought from cases verified through state cancer registry linkage (N = 1,622), because of insufficient information on tissue location. We sought tissue from the 2,021 cases verified using medical records, and received tissue from 882. When hospitals were contacted within 10 years of diagnosis, we received 87% of tissue materials; beyond that 10-year mark, we received 32%. Compared with the 2,761 colorectal cancer cases without tissue, the 882 cases with tissue were more likely to be alive, diagnosed more recently during follow-up, and had less-advanced staged disease. Cases with and without tissues were similar with respect to age at diagnosis, smoking, body mass index, physical activity, and other epidemiologic factors. Conclusions: Some of the most important elements in forming a tissue repository included having the cases' hospital contact and surgical accession information as well as contacting patients/next-of-kin and hospitals within 10 years of surgery. Impact: This tissue repository will serve as an important resource for colorectal cancer studies. See all the articles in this CEBP Focus section, “Biomarkers, Biospecimens, and New Technologies in Molecular Epidemiology.” Cancer Epidemiol Biomarkers Prev; 23(12); 2694–702. ©2014 AACR.
Bioinformatics for Clinical Next Generation Sequencing
Oliver, Gavin R. , Hart, Steven N. , Klee, Eric W. , Hart, Steven N

Mayo Clinic

Clinical Chemistry | December 2, 2014 | Volume: 61 | Issue: 1 | Pages: 124-135

10.1373/clinchem.2014.224360 | PMID 25451870 Get It

Abstract BACKGROUND Next generation sequencing (NGS)-based assays continue to redefine the field of genetic testing. Owing to the complexity of the data, bioinformatics has become a necessary component in any laboratory implementing a clinical NGS test. CONTENT The computational components of an NGS-based work flow can be conceptualized as primary, secondary, and tertiary analytics. Each of these components addresses a necessary step in the transformation of raw data into clinically actionable knowledge. Understanding the basic concepts of these analysis steps is important in assessing and addressing the informatics needs of a molecular diagnostics laboratory. Equally critical is a familiarity with the regulatory requirements addressing the bioinformatics analyses. These and other topics are covered in this review article. SUMMARY Bioinformatics has become an important component in clinical laboratories generating, analyzing, maintaining, and interpreting data from molecular genetics testing. Given the rapid adoption of NGS-based clinical testing, service providers must develop informatics work flows that adhere to the rigor of clinical laboratory standards, yet are flexible to changes as the chemistry and software for analyzing sequencing data mature.
Identification of Hospital Outliers in Bleeding Complications After Percutaneous Coronary Intervention
Hess, Connie N. , McCoy, Lisa A., Spertus, John A. , Krone, Ronald J. , Weaver, W. Douglas, Peterson, Eric D., Rao, Sunil V. , Neely, Megan L, Neely, Megan Lee , Singh, Mandeep , Peterson, Eric D. , Spertus, John A

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | November 26, 2014 | Volume: 8 | Issue: 1 | Pages: 15-22

10.1161/circoutcomes.113.000749 | PMID 25424242 Get It

Background— Post-percutaneous coronary intervention (PCI) bleeding complications are an important quality metric. We sought to characterize site-level variation in post-PCI bleeding and explore the influence of patient and procedural factors on hospital bleeding performance. Methods and Results— Hospital-level bleeding performance was compared pre- and postadjustment using the newly revised CathPCI Registry ® bleeding risk model (c-index, 0.77) among 1292 National Cardiovascular Data Registry ® hospitals performing >50 PCIs from 7/2009 to 9/2012 (n=1 984 998 procedures). Using random effects models, outlier sites were identified based on 95% confidence intervals around the hospital’s random intercept. Bleeding 72 hours post-PCI was defined as: arterial access site, retroperitoneal, gastrointestinal, or genitourinary bleeding; intracranial hemorrhage; cardiac tamponade; nonbypass surgery–related blood transfusion with preprocedure hemoglobin ≥8 g/dL; or absolute decrease in hemoglobin value ≥3 g/dL with preprocedure hemoglobin ≤16 g/dL. Overall, the median unadjusted post-PCI bleeding rate was 5.2% and varied among hospitals from 2.6% to 10.4% (5th, 95th percentiles). Center-level bleeding variation persisted after case-mix adjustment (2.8%–9.5%; 5th, 95th percentiles). Although hospitals’ observed and risk-adjusted bleeding ranks were correlated (Spearman ρ: 0.88), individual rankings shifted after risk-adjustment (median Δ rank order: ±91.5; interquartile range: 37.0, 185.5). Outlier classification changed postadjustment for 29.3%, 16.1%, and 26.5% of low-, non-, and high-outlier sites, respectively. Hospital use of bleeding avoidance strategies (bivalirudin, radial access, or vascular closure device) was associated with risk-adjusted bleeding rates. Conclusions— Despite adjustment for patient case-mix, there is wide variation in rates of hospital PCI-related bleeding in the United States. Opportunities may exist for best performers to share practices with other sites.
Hypoxia-Induced SUMOylation of E3 Ligase HAF Determines Specific Activation of HIF2 in Clear-Cell Renal Cell Carcinoma
Koh, Mei Yee , Nguyen, Vuvi, Lemos, Robert, Darnay, Bryant G., Kiriakova, Galina M., Abdelmelek, Mena, Ho, Thai H. , Monzon, Federico A. , Powis, Garth , Karam, Jose Antonio , Jonasch, Eric W. , Ho, Thai , Koh, Mei Yee

Mayo Clinic

Cancer Research | November 24, 2014 | Volume: 75 | Issue: 2 | Pages: 316-329

10.1158/0008-5472.can-13-2190 | PMID 25421578 Get It

Abstract Clear-cell renal cell cancer (CRCC) is initiated typically by loss of the tumor-suppressor VHL, driving constitutive activation of hypoxia-inducible factor-1 (HIF1) and HIF2. However, whereas HIF1 has a tumor-suppressor role, HIF2 plays a distinct role in driving CRCC. In this study, we show that the HIF1α E3 ligase hypoxia-associated factor (HAF) complexes with HIF2α at DNA to promote HIF2-dependent transcription through a mechanism relying upon HAF SUMOylation. HAF SUMOylation was induced by hypoxia, whereas HAF-mediated HIF1α degradation was SUMOylation independent. HAF overexpression in mice increased CRCC growth and metastasis. Clinically, HAF overexpression was associated with poor prognosis. Taken together, our results show that HAF is a specific mediator of HIF2 activation that is critical for CRCC development and morbidity. Cancer Res; 75(2); 316–29. ©2014 AACR.
Interventional pulmonology: The tipping point
Maldonado, Fabien , Edell, Eric S. , Barron, Patrick J., Yung, Rex

Mayo Clinic

Respirology | November 13, 2014 | Volume: 20 | Issue: 1 | Pages: 11-12

10.1111/resp.12431 | PMID 25393062 Get It